These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20097381)

  • 1. Re: Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. S. T. dos Reis, J. Pontes, Jr., F. E. Villanova, P. M. D. Borra, A. A. Antunes, M. F. Dall'oglio, M. Srougi and K. R. M. Leite. J Urol 2009; 181: 2320-2325.
    Ahirwar DK; Mittal RD
    J Urol; 2010 Mar; 183(3):1258. PubMed ID: 20097381
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. S. I. Berndt, J. L. Dodson, W. Y. Huang and K. K. Nicodemus, J Urol 2006; 175: 1613-1623.
    Rukin NJ; Luscombe CJ; Strange RC
    J Urol; 2007 Jan; 177(1):404. PubMed ID: 17162099
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features: R. J. Cohen, B. A. Shannon, M. Phillips, R. E. Moorin, T. M. Wheeler and K. L. Garrett J Urol 2008; 179: 1762-1767.
    Mai KT; Veinot JP
    J Urol; 2008 Dec; 180(6):2714; author reply 214-5. PubMed ID: 18951578
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories: E. A. Klein, F. J. Bianco, A. M. Serio, J. A. Eastham, M. W. Kattan, J. E. Pontes, A. J. Vickers and P. T. Scardino J Urol 2008; 179: 2212-2217.
    Sivanandam A; Bhandari M
    J Urol; 2008 Dec; 180(6):2716-7; author reply 2717-8. PubMed ID: 18951589
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.
    Ntais C; Polycarpou A; Ioannidis JP
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1395-402. PubMed ID: 14693728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: A multi-institutional evaluation of active surveillance for low risk prostate cancer. S. E. Eggener, A. Mueller, R. K. Berglund, R. Ayyathurai, C. Soloway, M. S. Soloway, R. Abouassaly, E. A. Klein, S. J. Jones, C. Zappavigna, L. Goldenberg, P. T. Scardino, J. A. Eastham and B. Guillonneau J Urol 2009; 181: 1635-1641.
    Ayres BE; Bott SR; Barber NJ; Langley SE; Montgomery BS
    J Urol; 2010 Sep; 184(3):1223-4; author reply 1224. PubMed ID: 20655069
    [No Abstract]   [Full Text] [Related]  

  • 10. Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.
    Li M; Guan TY; Li Y; Na YQ
    Chin Med J (Engl); 2008 Feb; 121(4):305-8. PubMed ID: 18304461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China.
    Li Y; Jin X; Kang S; Wang Y; Du H; Zhang J; Guo W; Wang N; Fang S
    Gynecol Oncol; 2006 Apr; 101(1):92-6. PubMed ID: 16278009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer.
    Elander N; Söderkvist P; Fransén K
    Anticancer Res; 2006; 26(1B):791-5. PubMed ID: 16739355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer.
    Decock J; Paridaens R; Ye S
    Clin Genet; 2008 Mar; 73(3):197-211. PubMed ID: 18177467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Best practice statement on cryosurgery for the treatment of localized prostate cancer R. J. Babaian, B. Donnelly, D. Bahn, J. G. Baust, M. Dineen, D. Ellis, A. Katz, L. Pisters, D. Rukstalis, K. Shinohara and J. B. Thrasher J Urol 2008; 180: 1993-2004.
    Gans W
    J Urol; 2009 May; 181(5):2388. PubMed ID: 19303086
    [No Abstract]   [Full Text] [Related]  

  • 15. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis.
    Shaik AP; Jamil K; Das P
    Urol J; 2009; 6(2):78-86. PubMed ID: 19472123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer].
    Tong M; Xu Z; Ai JK; Yuan YM; Yin Y; Wang JQ; Li HW; Liu JH; Xin DQ; Zhou LQ; Li M; Na YQ
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1493-6. PubMed ID: 15733480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
    Schellhammer PF
    J Urol; 2010 Mar; 183(3):1258-9; author reply 1259. PubMed ID: 20097380
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J. A. Smith, Jr., R. C. Chan, S. S. Chang, S. D. Herrell, P. E. Clark, R. Baumgartner and M. S. Cookson. J Urol 2007; 178: 2385-2390.
    Canes D
    J Urol; 2008 Jul; 180(1):410-1; author reply 411. PubMed ID: 18499156
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% K. Touijer, F. Rabbani, J. R. Otero, F. P. Secin, J. A. Eastham, P. T. Scardino And B. Guillonneau J Urol 2007; 178: 120-124.
    Joseph JV; Greene T
    J Urol; 2008 Feb; 179(2):789-90. PubMed ID: 18082824
    [No Abstract]   [Full Text] [Related]  

  • 20. [Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer].
    Tong M; Ai JK; Yuan YM; Yin Y; Zhou LQ; Xin DQ; Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1319-21. PubMed ID: 16029630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.